

ARTICLE

# Novel promoter and exon mutations of the *BMPR2* gene in Chinese patients with pulmonary arterial hypertension

Hu Wang<sup>1,3</sup>, Wen Li<sup>2,3</sup>, Weili Zhang<sup>1</sup>, Kai Sun<sup>1</sup>, Xiaodong Song<sup>1</sup>, Shuo Gao<sup>1</sup>, Channa Zhang<sup>1</sup>, Rutai Hui<sup>\*1</sup> and Hong Hu<sup>\*2</sup>

<sup>1</sup>Sino-German Laboratory for Molecular Medicine, FuWai Cardiovascular Hospital and Cardiovascular Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; <sup>2</sup>Department of Respiratory Medicine, China PLA General Hospital, Beijing, China

Pulmonary arterial hypertension (PAH), which is clinically characterized by a sustained elevation in mean pulmonary artery pressure leading to significant morbidity and mortality, is caused by intense remodeling of small pulmonary arteries by endothelial and smooth muscle proliferation. Genetic studies in familial PAH (FPAH) have revealed heterozygous germline mutations in the bone morphogenetic protein type II receptor (*BMPR2*), a receptor for the transforming growth factor (TGF)- $\beta$ /BMP superfamily. In this study, we conducted mutation screening in the promoter region and the entire coding regions as well as the intron/exon boundaries of the *BMPR2* gene in 20 Chinese patients with either idiopathic or FPAH. All novel detected mutations were excluded by their presence in a panel of 200 chromosomes from normal individuals. A novel mutation, G-669A, in the promoter sequence of the *BMPR2* gene was identified in one patient with FPAH, and no exonic mutations were detected in the proband. This mutation abolished a potential specificity protein 3 (sp3) transcription factor-binding site, and a dual luciferase assay showed that the promoter carrying the -669A allele had significantly decreased transcriptional activity compared with -669G allele. Of the other 19 patients, three novel heterozygous exonic mutations were identified: a frame shift mutation with deletion of TG at the nucleotide position 608–609 in exon 5 (Leu203fsX15), a nonsense mutation at the nucleotide position 292 in exon 3 (Glu98X) and a missense single nucleotide substitution in exon 12 (Ser863Asn).

*European Journal of Human Genetics* (2009) 17, 1063–1069; doi:10.1038/ejhg.2009.3; published online 18 February 2009

**Keywords:** bone morphogenetic protein receptor 2; pulmonary arterial hypertension; specificity protein 3

\*Correspondence: Dr R Hui, Sino-German Laboratory for Molecular Medicine, FuWai Cardiovascular Hospital and Cardiovascular Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, 100037 Beijing, China.

Tel: +86 10 88398154; Fax: +86 10 68331730;

E-mail: huirutai@sglab.org or Dr H Hu, Department of Respiratory Medicine, China PLA General Hospital, 28 Fuxing Road, 100852 Beijing, China.

Tel: +86 10 88398062; Fax: +86 10 68331730;

E-mail: huhong\_dr@yahoo.com.cn

<sup>3</sup>These authors contributed equally to this work.

Received 18 June 2008; revised 3 December 2008; accepted 8 January 2009; published online 18 February 2009

## Introduction

Pulmonary arterial hypertension (PAH) is characterized by widespread obstruction and obliteration of the small pulmonary arteries with an estimated incidence of 1–2 per million cases per year, and a median survival from diagnosis of only 2.8 years.<sup>1</sup> The arterial obstruction and obliteration cause a sustained elevation of pulmonary artery pressure and lead to right-heart failure with exercise limitation, palpitations, syncope and death.<sup>2</sup> The development of PAH mainly affects small pulmonary arteries in which there is intense remodeling resulting in intimal

thickening and medial hypertrophy because of an abnormal proliferation of smooth muscle and endothelial cells.<sup>3,4</sup>

The most significant advance in understanding the pathogenesis of PAH has been the demonstration of germline mutations in the familial form of this disease that have been mapped to a single locus designated PPH1 (OMIM 178600) on chromosome 2q31–32.<sup>5</sup> Subsequently, two independent groups identified heterozygous germline mutations in the gene encoding the bone morphogenetic protein type II receptor (BMP2), a member of the transforming growth factor (TGF)- $\beta$  superfamily of transmembrane serine/threonine kinase receptors, in patients with familial PAH (FPAH).<sup>6,7</sup> Although mutations in the *BMP2* gene (OMIM 600799) are present in more than approximately 70% of FPAH and up to 40% of patients with apparently sporadic idiopathic PAH (IPAH),<sup>8–10</sup> no mutations in the promoter regions of the *BMP2* gene have been found to be associated with PAH. In this study, we reported, for the first time, a novel mutation G-669A in the promoter sequences and three novel exonic mutations of the *BMP2* in Chinese patients with PAH.

## Materials and methods

### Patients' data

Twenty unrelated patients with either IPAH or FPAH were enrolled. At the time of enrollment, the patients provided written informed consent according to a protocol approved by the institutional review board of the Cardiovascular Institute, Chinese Academy of Medical Sciences. Blood samples, detailed family histories and medical records were obtained. A review of complete medical records confirmed the diagnosis of IPAH or FPAH according to consensus standards.<sup>11</sup> In brief, the diagnosis of IPAH required that a consultant with expertise in pulmonary vascular disease confirm the following: (1) mean pulmonary arterial pressure (PAP) >25 mm Hg, with a pulmonary capillary

wedge pressure  $\leq$ 15 mm Hg, both measured at rest by right heart catheterization and (2) the exclusion of other disorders known to cause pulmonary hypertension by clinical evaluation and objective tests, for example, ventilation and perfusion lung scans to exclude pulmonary embolism, contrast echocardiography and/or measurements of oxygen saturation during cardiac catheterization to exclude intracardiac shunting, and echocardiography and cardiac catheterization to exclude left heart disease.

### Mutation detection

Genomic DNA was isolated from peripheral blood leukocytes with a standard salting-out protocol. The 2022 bp length sequences upstream of the initiation codon (nucleotides are numbered according to the DNA sequence, with the adenosine of the initiation codon assigned position +1) were divided into four fragments for amplification. PCR primers were designed to amplify the coding regions and the intron/exon boundaries of the *BMP2* gene in the 20 patients and a panel of 200 chromosomes from normal blood donors who were from the same ethnic/regional origin and age and gender matched with the patients. The sequences of each set of primers and PCR conditions are described in Table 1. The PCR products were purified and analyzed by direct sequencing using an ABI 3730 (Applied Biosystems, CA, USA). All novel detected mutations were excluded by their presence in a panel of 200 chromosomes from normal blood donors.

### Construction of luciferase reporter plasmids

Two 300 bp fragments, which carry the –669G and –669A allele, respectively, were amplified from the *BMP2* gene promoter region with specific primers (forward primer: 5'-GCAGCCTCTCACACCCACT and reverse primer: 5'-GGCAGCCCTAGTCGCATC). The PCR products which carry –669G and –669A allele were purified and cloned into the pGL3 basic vector fused with a luciferase reporter

**Table 1** The primer sequences used for PCR amplification

Exon	Sense primer	Antisense primer	Annealing $T_m$	Product length
Exon 1	5'-GGCTGTTTCTCCGCCGGTCTA-3'	5'-GGGTGGGAATATGGAAGTGGG-3'	58.9°C	368 bp
Exon 2	5'-TCATGAACAGAAGAACGTCATT-3'	5'-CACAGTCATTTACAGTAAGGA-3'	58.9°C	374 bp
Exon 3	5'-GAAACTCCGCCCTCAATAA-3'	5'-GAGACGGGATTTACACCAG-3'	51.2°C	632 bp
Exon 4	5'-AGGAGCACATCTACTTGG-3'	5'-ATACATTTGAGGCTGGGT-3'	51.2°C	483 bp
Exon 5	5'-TGGCTTTTCATGCTATTCTGC-3'	5'-CCCCTTTTTCATCACTTTCTTAT-3'	51.2°C	588 bp
Exon 6	5'-AGGCTGGGTCTGGTAGGA-3'	5'-CCGGGTTCAAGCAATTCTC-3'	58.9°C	652 bp
Exon 7	5'-TGGAATCCTAGCCTATTT-3'	5'-ACTCAGCTATCAAGCACC-3'	51.2°C	452 bp
Exon 8	5'-GTATGTTCAATTCATGTTCAATAGTCC-3'	5'-AATTATCATTCAAAGTACATCAGTGTG-3'	51.2°C	315 bp
Exon 9	5'-ACATGGTTAGGGTCAAAT-3'	5'-GATGGTGATAAAGGAAAA-3'	51.2°C	575 bp
Exon 10	5'-TTCCAAATGTGCCTGAAGGG-3'	5'-TGTGGCATTAGGCAACTCAA-3'	51.2°C	401 bp
Exon 11	5'-GAGCATGTTCCGTAATCC-3'	5'-TTGTTGGGTCTCAGTTTC-3'	51.2°C	393 bp
Exon 12-1	5'-TGTACGTTTGAAGAAAATG-3'	5'-ATTGTATTCATCTTGGCAACTC-3'	51.2°C	913 bp
Exon 12-2	5'-GCAACTGGACAGCAGACTT-3'	5'-AATAGTTATTTAAATGGCCCA-3'	51.2°C	779 bp
Exon 13	5'-CCAAGTTAAGATCGCTACCA-3'	5'-TGACAGGAGGATAAAGCAGT-3'	51.2°C	670 bp

gene (Promega, Madison, WI, USA), generating two luciferase reporter constructs: pGL3-BM $PR2$ -wild (carrying the -669G allele) and pGL3-BM $PR2$ -mut (carrying the -669A allele). The two luciferase reporter constructs were sequenced to confirm the integrity and the presence of the desired mutation in the constructs. The pGL3 basic vector containing no promoter element was used as negative control and the pGL3 promoter vector fused with SV40 promoter element was used as positive control.

### Cell culture

Human pulmonary artery endothelial cells (Cascade Biologics, Portland, OR, USA) were cultured in medium 200 (Cascade Biologics) supplemented with low serum growth supplement (Cascade Biologics). Human pulmonary artery smooth muscle cells (Cascade Biologics) were cultured in medium 231 (Cascade Biologics) supplemented with smooth muscle differentiation supplement (Cascade Biologics). The two cell cultures were supplemented with 10% fetal bovine serum (FBS, HyClone, Logan, UT, USA), 100  $\mu$ g/ml penicillin, 100  $\mu$ g/ml streptomycin, and kept in an atmosphere of 95% air, 5% CO $_2$  in a 37°C humidified incubator.

### Transfection and luciferase assay

Human pulmonary artery endothelial cells and human pulmonary artery smooth muscle cells were cultured in 12-well plates. The cells were transfected transiently with the pGL3-BM $PR2$ -wild and pGL3-BM $PR2$ -mut vectors using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). After 48 h, cell lysates were prepared with the Dual-Luciferase reporter assay system (Promega, Madison, WI, USA), and both *Firefly* and *Renilla* luciferase activities were measured in a Veritas Microplate Luminometer (Turner, Sunnyvale, CA, USA). The transfection efficiency was normalized according to the *Renilla* luciferase activity. Each transfection was carried out in quintuplicate and repeated three times.

### Statistical analysis

All data were expressed as mean  $\pm$  SD. Differences between groups were examined for statistical significance using Student's *t*-test. A *P*-value <0.05 denoted the presence of a statistically significant difference.


## Results

### Genetic findings

To detect variants presenting in the promoter region of the *BMPR2* gene that potentially regulate the level of gene transcription, the 2022 bp length sequence upstream of the initiation codon was amplified in 20 IPAH or FPAH patients. Direct sequencing of the PCR products revealed that one patient with FPAH carried a novel heterozygous substitution mutation G-669A in the promoter region of the *BMPR2* gene and no other mutations were found in any of the 13 exons in the proband (Figures 1 and 2). The other 19 PAH patients and the panel of 200 chromosomes from normal individuals were found not to harbor this mutation. Of the other 19 patients, three novel heterozygous exonic mutations were identified: a frame shift mutation with deletion of TG at the nucleotide position 608–609 in exon 5 (Leu203fsX15), a nonsense mutation at the nucleotide position 292 in exon 3 (Glu98X) and a missense single nucleotide substitution in exon 12 (Ser863Asn). Moreover, only one mutation, Cys66Arg, in exon 2 was found to be one of the more than 140 previously reported mutations in this study (Table 2).

### Clinical findings

Figures 1 and 2 show the pedigree of the proband (II-2) carrying the G-669A mutation. The proband was a 38-year-old female who was diagnosed at the age of 36 with dyspnea on exertion, hemoptysis and severe PAH. Echocardiography showed an enlarged right atrium (RA) and



**Figure 1** The pedigree map of the familial pulmonary arterial hypertension family from China.


**Table 2** *BMPR2* mutations in Chinese PAH patients<sup>a</sup>

Sex	Age (years)	Location	Domain	Mutation type	Nucleotide change	Amino-acid change	IPAH or FPAH
Female	43	Exon 2	ECD	Missense	c.196T>C	Cys66Arg	IPAH
Female	34	Exon 3	ECD	Nonsense	c.292G>T	Glu98X <sup>b</sup>	IPAH
Female	20	Exon 5		Frameshift	c.608-609delTG	Leu203fsX15 <sup>b</sup>	IPAH
Male	34	Exon 12	CD	Missense	c.2588G>A	Ser863Asn <sup>b</sup>	FPAH

CD, cytoplasmic domain; ECD, extracellular domain; FPAH, familial pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension.

<sup>a</sup>GenBank reference sequence and version number for *BMPR2*: NM\_001204.6; numbering is based on +1 as A of the ATG initiation codon.

<sup>b</sup>Novel mutations reported in this study.



**Figure 2** Sequence analysis of the heterozygous *BMPR2* G-669A mutation in the proband. (a) and (b) indicate the forward and reverse sequence analyses of the *BMPR2* gene promoter region in a healthy control individual, respectively. The G-669A mutation present in the proband (II-2) is shown in (c) and (d), which indicate the *BMPR2* forward and reverse sequence analyses.

right ventricle (RV) with regurgitation through the tricuspid valve. Right heart catheterization revealed elevated PAP: 74/30 (46) mm Hg. The proband's brother and father had similar clinical manifestations and both died of IPAH in their twenties (Figure 1).

#### ***BMPR2* promoter carrying the -669A allele has decreased transcription activity compared with the -669G allele**

To verify the effect of the variants -669A and -669G on the transcriptional activity of the *BMPR2* gene, two luciferase reporter vectors, which contain -669A allele or -669G allele, were constructed. Human pulmonary artery endothelial cells and human pulmonary artery smooth muscle cells were transiently transfected with the two vectors and luciferase activities were measured. The results showed that the *BMPR2* promoter carrying the -669A allele showed significantly decreased transcriptional activity compared with that carrying the -669G allele in human pulmonary artery endothelial cells (Figure 3a) and in human pulmonary artery smooth muscle cells (Figure 3b).

#### **Identification of putative transcription factor-binding sites affected by the -669G and -669A alleles of *BMPR2* gene**


Using the MAPPER Search Engine,<sup>12</sup> we identified a putative transcription factor-binding site affected by the -669G and -669A alleles. Figure 4b shows that the *BMPR2* promoter carrying the -669G contains a consensus-binding site for specificity protein 3 (sp3) transcription factor. G-669A mutation abolishes the sp3-binding site

(Figure 4a). This change (-669G>A) altered the highly conserved G base in the sp3-binding site (Figure 4c).

#### **Discussion**


This is the first report that a mutation in the promoter sequence of the *BMPR2* gene is associated with FPAH. In earlier studies, extensive analyses of the *BMPR2* gene have been conducted in patients with FPAH and IPAH from a wide range of ethnic groups. Recently, two novel missense mutations of *BMPR2* gene have been identified in two Chinese families with PAH.<sup>13,14</sup> Mutations of *BMPR2* gene have been detected in up to 70% of recognized FPAH cases, whereas in IPAH, the reported mutation detection rate ranges from 11 to 40%.<sup>8-10</sup> All the defects of *BMPR2* gene identified in patients, which include all major mutation classes, with single nucleotide substitutions resulting in nonsense,<sup>6-10,15-20</sup> missense,<sup>6-10,15-18,21-25</sup> or splice site mutation,<sup>9,15,17,21</sup> and small insertions or deletions<sup>6-9,15-17,19,21,22,26-29</sup> are observed in exons, introns or intron/exon boundaries. No mutations were reported to be found in the promoter region of *BMPR2* gene in patients with FPAH or IPAH previously. In this study, a novel heterozygous substitution mutation, G-669A, in the promoter sequence of *BMPR2* gene was identified in a Chinese patient with FPAH.

The TGF- $\beta$  superfamily of ligands and receptors may be divided into two principal classes, termed the TGF- $\beta$ s and BMPs, based on sequence comparison and Smad-dependent intracellular signaling activity. BMPs are the largest group of cytokines within the TGF- $\beta$  superfamily and are involved in the regulation of proliferation,



**Figure 3** Transcriptional activity analysis of the *BMPR2* promoter containing the  $-669G$  and  $-669A$  alleles. Two luciferase reporter constructs (pGL3-BMPR2-wild and pGL3-BMPR2-mut) containing 300 bp of the *BMPR2* promoter sequence, which carry  $-669G$  and  $-669A$  alleles, respectively were introduced into human pulmonary artery endothelial cells and human pulmonary artery smooth muscle cells for transient expression assays. After 48 h, cells were lysed and luciferase activities were assayed. *Firefly* luciferase activities expressed were normalized on the basis of *Renilla* luciferase activity encoded by the cotransfected control plasmid, pRL-CMV. The results showed that the luciferase activity of the *BMPR2* promoter containing the  $-669A$  allele (mutant) was significantly decreased compared with the  $-669G$  allele (wild type) in endothelial cells (a) and in smooth muscle cells (b). Each transfection was carried out in quintuplicate and repeated three times. Data shown are the means  $\pm$  SD,  $n = 5$  (\*compared with the relative luciferase activity of  $-669G$  allele in endothelial cells,  $P = 0.025$  and in smooth muscle cells,  $P = 0.015$ ). The pGL3 basic vector containing no promoter element was used as negative control and the pGL3 promoter vector fused with SV40 promoter element was used as positive control.

differentiation and apoptosis.<sup>30</sup> Signaling by BMP receptors involves heterodimerization of two transmembrane serine/threonine kinases: the constitutively active type II receptor, BMPR2, and a corresponding type I receptor, BMPR1A or BMPR1B. The most comprehensively investigated mediators of TGF- $\beta$  signal transduction are the Smad family and can be divided into three classes: receptor (R-) Smads, collaborating (Co-) Smads and inhibitory (I-) Smads. Of the three Smads, R-Smads 1/5 are specific to BMP signal flow. BMPR2 binds the specific ligands to initiate and propagate intracellular signal by activating R-Smads 1/5. Activated R-Smads form a heteromeric complex with Co-Smad 4, translocating to the nucleus, to control the transcriptional regulation of target genes.<sup>31,32</sup> R-Smads 2/3 are the



**Figure 4** Identification of putative transcription factor-binding sites affected by  $-669G$  and  $-669A$  alleles of *BMPR2* gene. Using the MAPPER Search Engine (<http://mapper.chip.org/>), we identified the putative transcription factor-binding sites affected by  $-669G$  and  $-669A$  alleles. (b) The *BMPR2* promoter carrying the  $-669G$  allele contains a consensus-binding site for sp3 transcription factor. After the G was changed to A, the sp3-binding site was abolished (a). This change ( $-669G > A$ ) altered the highly conserved G base in the sp3-binding site (c). The sequence motif of the profile representing the binding site is shown.

important mediators of TGF- $\beta$  signaling, their activation can lead to abnormal proliferative responses to TGF- $\beta$  and R-Smads 2/3 have been proved to functionally antagonize R-Smads 1/5 signaling.<sup>33–35</sup> Earlier studies have shown that *BMPR2* mutations lead to a loss of signaling through Smad1/5 in cells and animal models.<sup>25,36</sup> Thus, failure of BMP signaling through Smad1/5 in the vasculature can increase TGF- $\beta$ /Smad2/3 signaling, which highlights the potential importance of a loss of Smad1/5 signaling as cause of pulmonary vascular remodeling in patients with genetic PAH. In our study, the mutation  $-669A$  in the promoter sequence of *BMPR2* gene showed decreased transcriptional activity and may downregulate the expression of BMPR2 and weaken Smad1/5 signaling, similarly to *BMPR2* coding region mutations.

We performed a computer analysis of the 300 bp promoter sequence that carries the  $-669G$  allele using CpG Island Searcher (<http://www.uscnorris.com/cpgislands2/cpg.aspx>). The result showed that this promoter region is a potential CpG Island. Methylation of CpG sites within the promoters

of genes can lead to their silencing, and a feature found in a number of human cancers (for example, the silencing of tumor suppressor genes). In contrast, the demethylation of CpG sites has been associated with the overexpression of oncogenes within cancer cells. The -669G allele changed to -669A allele in the 300 bp promoter region of *BMPR2* gene might have abolished a potential CpG site and resulted in its demethylation. This demethylation might cause an upregulation of the transcriptional activity of the *BMPR2* gene. However, in our study, we found that the transcriptional activity of the *BMPR2* promoter sequence carrying -669A allele decreased significantly compared with -669G allele in luciferase activity assay experiments; therefore, we deduced that this potential CpG site might not be functional.

Searching in the MAPPER transcription factor database,<sup>12</sup> a potential sp3 transcription factor-binding site was identified in the *BMPR2* promoter sequence carrying the -669G allele, which is abolished by the G-669A mutation. This was of interest because sp3 is a well-known transcription factor with important regulatory effects on various cellular and viral promoters. The sp family of transcription factors binds and acts through GC boxes to regulate gene expression and is recognizable by a DNA-binding domain formed from three conserved Cys2His2 zinc fingers.<sup>37</sup> Within this family, sp3 and sp1 are ubiquitously expressed in mammalian cells, and sp3 is structurally similar to sp1, with similar affinities for the sp1-binding site, and participates in regulating the expression of genes involved in almost all cellular processes.<sup>38</sup> Sp3 has been shown to act as a transcriptional activator similar to sp1 in many studies.<sup>39–41</sup> Our results showed that the -669A mutant decreased luciferase transcriptional activity and had an abolished sp3 transcription factor-binding site. This suggests that sp3 may play an important role in the transcriptional regulation of *BMPR2* gene.

The *BMPR2* gene consists of 13 exons. The mature protein harbors four discrete functional domains, including an extracellular ligand-binding domain encoded by exons 1–3, a transmembrane domain generated by exon 4, a serine/threonine kinase domain from exon 5–11 and a very large intracellular C-terminal domain of unknown function from exons 12 and 13.<sup>16</sup> This large C-terminal domain is present only in *BMPR2* within the TGF- $\beta$  receptor superfamily. More than 140 distinct mutations of *BMPR2* gene have been identified in patients with PAH from a wide range of ethnic groups.<sup>8</sup> In this study, we identified three novel exonic mutations of the *BMPR2* gene in the Chinese PAH patients (Table 2), including a frame shift mutation in exon 5 (Leu203fsX15), a nonsense mutation in exon 3 (Glu98X) and a missense mutation in exon 12 (Ser863Asn). These disease-causing mutations are predicted to affect different domains of the *BMPR2* protein and mutations within different regions may vary in their impact on disease initiation and progression. Only one mutation (Cys66Arg) of more than 140 mutations reported

earlier has been found in Chinese PAH patients in this study. The ethnic group difference may be a potential explanation.

It is well known that nonsense, missense, splice site mutations and small insertions or deletions in the genes can lead to the expression of defective protein products, which are often responsible for a hereditary disease. In our study, we have reported four novel mutations of the *BMPR2* gene in Chinese patients with PAH. This posed some interesting questions, such as whether the disease can be caused by the reduced level of mRNA expression and further explorations in the future may provide us a complete picture of the role of *BMPR2* in the etiology of PAH

#### Acknowledgements

This study was supported by the National Natural Science Foundation of China (nos. 30570796 and 30600239).

#### References

- 1 Rubin LJ: Primary pulmonary hypertension. *N Engl J Med* 1997; **336**: 111–117.
- 2 Humbert M, Morrell NW, Archer SL *et al*: Cellular and molecular pathobiology of pulmonary arterial hypertension. *J Am Coll Cardiol* 2004; **43**: 13S–24S.
- 3 Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary arterial hypertension. *N Engl J Med* 2004; **351**: 1425–1436.
- 4 Cool CD, Stewart JS, Werahera P *et al*: Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. *Am J Pathol* 1999; **155**: 411–419.
- 5 Nichols WC, Koller DL, Slovis B *et al*: Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. *Nat Genet* 1997; **15**: 277–280.
- 6 Deng Z, Morse JH, Slager SL *et al*: Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. *Am J Hum Genet* 2000; **67**: 737–744.
- 7 Lane KB, Machado RD, Pauciuolo MW *et al*: Heterozygous germline mutations in *BMPR2*, encoding a TGF- $\beta$  receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. *Nat Genet* 2000; **26**: 81–84.
- 8 Machado RD, Aldred MA, James V *et al*: Mutations of the TGF- $\beta$  type II receptor *BMPR2* in pulmonary arterial hypertension. *Hum Mutat* 2006; **27**: 121–132.
- 9 Morisaki H, Nakanishi N, Kyotani S, Takashima A, Tomoike H, Morisaki T: *BMPR2* mutations found in Japanese patients with familial and sporadic primary pulmonary hypertension. *Hum Mutat* 2004; **23**: 632.
- 10 Thomson JR, Machado RD, Pauciuolo MW *et al*: Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding *BMPR2*, a receptor member of the TGF- $\beta$  family. *J Med Genet* 2000; **37**: 741–745.
- 11 McGoan M, Gutterman D, Steen V *et al*: Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. *Chest* 2004; **126**: 14S–34S.
- 12 Marinescu VD, Kohane IS, Riva A: MAPPER: a search engine for the computational identification of putative transcription factor binding sites in multiple genomes. *BMC Bioinformatics* 2005; **6**: 79.

- 13 Fu LJ, Zhou AQ, Huang MR *et al*: A novel mutation in the BMPR2 gene in familial pulmonary arterial hypertension. *Chin Med J (Engl)* 2008; **121**: 399–404.
- 14 Zhicheng J, Lihe L, Zhiyan H *et al*: Bone morphogenetic protein receptor-II mutation Arg491Trp causes malignant phenotype of familial primary pulmonary hypertension. *Biochem Biophys Res Commun* 2004; **315**: 1033–1038.
- 15 Koehler R, Grunig E, Pauciulo MW *et al*: Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension. *J Med Genet* 2004; **41**: e127.
- 16 Machado RD, Pauciulo MW, Thomson JR *et al*: BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. *Am J Hum Genet* 2001; **68**: 92–102.
- 17 Elliott CG, Glissmeyer EW, Havlena GT *et al*: Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. *Circulation* 2006; **113**: 2509–2515.
- 18 Humbert M, Deng Z, Simonneau G *et al*: BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. *Eur Respir J* 2002; **20**: 518–523.
- 19 Harrison RE, Berger R, Haworth SG *et al*: Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. *Circulation* 2005; **111**: 435–441.
- 20 Uehara R, Suzuki H, Kurokawa N *et al*: Novel nonsense mutation of the BMPR-II gene in a Japanese patient with familial primary pulmonary hypertension. *Pediatr Int* 2002; **44**: 433–435.
- 21 Cogan JD, Vnencak-Jones CL, Phillips III JA *et al*: Gross BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension. *Genet Med* 2005; **7**: 169–174.
- 22 Sankelo M, Flanagan JA, Machado R *et al*: BMPR2 mutations have short lifetime expectancy in primary pulmonary hypertension. *Hum Mutat* 2005; **26**: 119–124.
- 23 Roberts KE, McElroy JJ, Wong WP *et al*: BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. *Eur Respir J* 2004; **24**: 371–374.
- 24 Morrell NW, Yang X, Upton PD *et al*: Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. *Circulation* 2001; **104**: 790–795.
- 25 Rudarakanchana N, Flanagan JA, Chen H *et al*: Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. *Hum Mol Genet* 2002; **11**: 1517–1525.
- 26 Aldred MA, Vijayakrishnan J, James V *et al*: BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. *Hum Mutat* 2006; **27**: 212–213.
- 27 Trembath RC, Thomson JR, Machado RD *et al*: Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. *N Engl J Med* 2001; **345**: 325–334.
- 28 Sugiyama S, Hirota H, Yoshida M *et al*: Novel insertional mutation in the bone morphogenetic protein receptor type II associated with sporadic primary pulmonary hypertension. *Circ J* 2004; **68**: 592–594.
- 29 Abramowicz MJ, Van Haecke P, Demedts M, Delcroix M: Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation. *Eur Respir J* 2003; **22**: 560–562.
- 30 Miyazono K, Maeda S, Imamura T: BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. *Cytokine Growth Factor Rev* 2005; **16**: 251–263.
- 31 Massague J: TGF-beta signal transduction. *Annu Rev Biochem* 1998; **67**: 753–791.
- 32 Massague J, Seoane J, Wotton D: Smad transcription factors. *Genes Dev* 2005; **19**: 2783–2810.
- 33 Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P: Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. *EMBO J* 2002; **21**: 1743–1753.
- 34 Itoh S, Thorikay M, Kowanetz M *et al*: Elucidation of Smad requirement in transforming growth factor-beta type I receptor-induced responses. *J Biol Chem* 2003; **278**: 3751–3761.
- 35 Jeffery TK, Upton PD, Trembath RC, Morrell NW: BMP4 inhibits proliferation and promotes myocyte differentiation of lung fibroblasts via Smad1 and JNK pathways. *Am J Physiol Lung Cell Mol Physiol* 2005; **288**: L370–L378.
- 36 Yu PB, Beppu H, Kawai N, Li E, Bloch KD: Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells. *J Biol Chem* 2005; **280**: 24443–24450.
- 37 Suske G: The Sp-family of transcription factors. *Gene* 1999; **238**: 291–300.
- 38 Cawley S, Bekiranov S, Ng HH *et al*: Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. *Cell* 2004; **116**: 499–509.
- 39 Udvadia AJ, Templeton DJ, Horowitz JM: Functional interactions between the retinoblastoma (Rb) protein and Sp-family members: superactivation by Rb requires amino acids necessary for growth suppression. *Proc Natl Acad Sci USA* 1995; **92**: 3953–3957.
- 40 Ihn H, Trojanowska M: Sp3 is a transcriptional activator of the human alpha2(I) collagen gene. *Nucleic Acids Res* 1997; **25**: 3712–3717.
- 41 Zhao L, Chang LS: The human POLD1 gene. Identification of an upstream activator sequence, activation by Sp1 and Sp3, and cell cycle regulation. *J Biol Chem* 1997; **272**: 4869–4882.